Activity Details

0.5 AMA PRA Category 1 Credit
0.5 ANCC contact hour
0.5 APRN contact hour
Released: February 20, 2018
Expires: February 20, 2019
0.5 hour to complete

Jointly Provided By

Target Audience

Oncology clinicians, including physicians, nurses, nurse practitioners, and physician assistants

Learning Objectives

After completing this educational activity, the participant will demonstrate the ability to:

  1. Routinely use ASCO/CAP13 guidelines to determine HER2 status that guide management and assist in evaluating risk
  2. Integrate evolving targeted treatment paradigms into clinical practice for patients with HER2-positive breast cancer, based on efficacy and safety
  3. Utilize evidence-based and guideline recommendations for neoadjuvant and adjuvant treatments and appropriate treatment sequencing strategies for patients with HER2-positive breast cancer
  4. Develop a strong patient-provider collaborative approach to managing patients with breast cancer that includes multidisciplinary management, patient education, engagement, and shared decision making

Activity Description

Breast cancer is expected to affect over 250,000 American women in 2017, making it the most common cancer in women.1 When the disease is confined to the breast and regional lymph nodes, it is frequently curable. However, metastatic disease is significantly more challenging to treat and accounts for the majority of the over 40,000 breast cancer associated deaths in the United States per year.1 Contributing to this treatment challenge are the estimated 18% to 20% of patients with invasive breast cancer who overexpress the human epidermal growth factor receptor 2 (HER2), which is associated with more aggressive disease and poorer prognosis, but a markedly better response to the combination of chemotherapy and targeted agents.2 Over the last 2 decades, a number of advances have been made for treating patients with HER2-positive breast cancer, which has significantly improved outcomes in both early- and late-stage disease. However, resistance to HER2-targeted therapies and understanding the mechanisms contributing to a less than optimal response continues to be a challenge. Newer therapies are being developed to meet this need that have the potential to shift the treatment paradigm for patients with HER2-positive breast cancer. For now, the appropriate use of treatment guidelines, incorporation of evolving targeted treatment paradigms, and the ability to engage the patient in the decision-making process around therapeutic options, are key to improving outcomes for patients with HER2-positive breast cancer.

This activity is designed to be interactive and fast-paced, allowing you to test your knowledge and practice through a series of multiple choice questions. The activity includes case vignettes, an opportunity to compare yourself to your peers, and to learn what the expert has to say about treatment approaches in HER2-positive breast cancer.


  1. Siegel RL, Miller KD, Jemal A. Cancer Statistics. 2017. CA Cancer J Clin. 2017;67(1):7-30.
  2. Santa-Maria CA, Nye L, Mutonga MB, Jain S, Gradishar WJ. Management of Metastatic HER2-Positive Breast Cancer: Where Are We and Where Do We Go From Here? Oncology (Williston Park). 2016;30(2):148-155.


Hope S. Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Hope S. Rugo, MD, has affiliations with Eisai, Genentech, Lilly, Macrogenics, Merck, Novartis, OBI Pharma, Pfizer, and Plexxikon – all funding to UC Regents only (Contracted Research).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

RMEI Medical Education, LLC
Carrie Noriega, MD, has no affiliations with commercial interests to disclose.
Lobna M. Eldasher, PharmD, has no affiliations with commercial interests to disclose.
Sharon Powell, has no affiliations with commercial interests to disclose.

Postgraduate Institute for Medicine

The PIM planners and managers, Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, MBA, MSN, RN; and Jan Schultz, MSN, RN, CHCP, have nothing to disclose. 

Joint Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour.

Designated for 0.5 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, registered nurses, and physician assistants are entitled to receive up to 0.5 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, registered nurses, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Technical Support

For any technical issues or issues with your CME Certificate, please visit:

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.